Skip to content
All resources

Growth hormone peptides

What Is Ipamorelin? Structure, Receptor, Evidence and Regulatory Status

EC

By

· 9 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 7 sections
  1. What kind of molecule is ipamorelin?
  2. How is ipamorelin thought to work?
  3. What does "selective" mean for ipamorelin?
  4. What has ipamorelin been studied for?
  5. Is ipamorelin approved anywhere?
  6. What is ipamorelin commonly confused with?
  7. Frequently asked questions

Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, that makes the pituitary release its own growth hormone by activating the ghrelin receptor. Novo Nordisk chemists described it in 1998 as the first selective growth hormone secretagogue, because in pigs it released growth hormone without the ACTH and cortisol rise seen with older peptides. Its human record is one pharmacokinetic study and a gut-recovery programme after bowel surgery that did not meet its endpoint. It is approved nowhere, including Canada.

A short five-bead chain of glass beads in teal and navy
Illustration, not the exact structure: ipamorelin is a pentapeptide.

What kind of molecule is ipamorelin?

It is a small, deliberately unnatural peptide. Three of its five residues do not occur in ordinary proteins: Aib (2-aminoisobutyric acid), D-2-naphthylalanine and D-phenylalanine. The C-terminus is amidated. Raun and colleagues report that it came out of a large chemistry programme that started from an older growth hormone-releasing peptide, GHRP-1, and removed its central Ala-Trp dipeptide (PMID 9849822). The same group later used it as the starting point for further, more potent analogues, which is a sign of how it was seen inside Novo Nordisk: as a scaffold as much as a product.

PropertyIpamorelin
SequenceAib-His-D-2-Nal-D-Phe-Lys-NH2 (five residues)
CAS number170851-70-4
Molecular formulaC38H49N9O5
Molecular weightAbout 712 g/mol
Development codeNNC 26-0161
ClassGhrelin-receptor (GHS-R1a) agonist; growth hormone secretagogue
NotA GHRH analogue, and not growth hormone itself
Evidence stageCell and animal work; two small human studies published
Regulatory statusApproved nowhere; named in Health Canada's April 2026 advisory

The identifiers come from the public chemical record (PubChem). A molecular weight on a certificate should agree with that figure within the instrument's tolerance, which is the simplest identity check a buyer of laboratory material can make. The general argument is in what a certificate of analysis establishes.

How is ipamorelin thought to work?

The pituitary cells that make growth hormone carry two separate stimulatory receptors. One answers growth hormone-releasing hormone (GHRH) from the hypothalamus. The other is the growth hormone secretagogue receptor, now usually called the ghrelin receptor, after the stomach hormone identified as its natural ligand. Ipamorelin acts at the second one. In Raun's pharmacological profiling with GHRP and GHRH antagonists, it released growth hormone through the GHRP-type receptor, as GHRP-6 does, and not through the GHRH receptor.

That one fact sorts out most of the confusion around the name. Ipamorelin is often discussed beside CJC-1295 and tesamorelin, but those two are GHRH analogues acting at the other receptor. The two-family map is in growth hormone secretagogues explained, and the receptor itself, including the fact that it signals even with nothing bound, is covered in the ghrelin receptor explainer.

What does "selective" mean for ipamorelin?

It means something narrow and specific. In Raun's 1998 paper, ipamorelin released growth hormone from rat pituitary cells with potency close to GHRP-6, reaching 85% of GHRP-6's maximal response. In anaesthetised rats and conscious swine the two were again closely matched. The selectivity finding came from the swine only. GHRP-6 and GHRP-2 raised ACTH and cortisol. Ipamorelin did not raise either beyond the levels seen after GHRH, even at amounts more than 200 times its half-maximal level for growth hormone release. None of the compounds changed FSH, LH, prolactin or TSH.

So "selective" is a statement about hormone specificity in pigs. It is not a human measurement, it is not a safety finding, and it did not separate ipamorelin from the older peptides on prolactin, because none of them moved prolactin in that study. Exactly what was and was not measured, and in which species, is laid out in ipamorelin vs GHRP-6 and GHRP-2. Why both selectivity and half-life figures depend on the assay behind them is covered in ipamorelin half-life and selectivity.

What has ipamorelin been studied for?

By evidence stage, the record is short enough to list in full.

Cells. Rat pituitary cell work established its potency and the receptor it uses (PMID 9849822).

Animals. In adult female rats, Johansen and colleagues reported that ipamorelin increased longitudinal bone growth in the tibia in step with the amount given, from 42 to as much as 52 micrometres per day, with no change in total IGF-I or in serum markers of bone turnover (PMID 10373343). Svensson and colleagues then gave ipamorelin, GHRP-6 or growth hormone to young adult female rats for 12 weeks. All three raised bone mineral content by DXA, but more detailed measurement showed this came from bigger bones, with volumetric bone mineral density unchanged (PMID 10828840). That distinction, larger bones rather than denser bone, is the kind of detail that summaries tend to drop. In a rat model of postoperative ileus, ipamorelin shortened the time to the first bowel movement after abdominal surgery (PMID 19289567).

Humans. Two published studies. Gobburu and colleagues ran an escalating-exposure study in healthy men, eight at each of five levels. They reported a terminal half-life of about two hours and a single episode of growth hormone release peaking at about 40 minutes, falling to negligible levels at every level studied (PMID 10496658). Beck and colleagues then ran a phase 2, double-blind, placebo-controlled trial in adults after bowel resection (NCT00672074). Of 117 enrolled, 114 were analysed. Median time to the first tolerated solid meal was 25.3 hours with ipamorelin against 32.6 hours with placebo, a difference that was not statistically significant (p = 0.15), and the authors found no significant differences in the key or secondary efficacy analyses (PMID 25331030).

A second, larger phase 2 trial in the same setting is registered as NCT01280344. The registry lists 320 participants, completion in May 2014, and no posted results. We found no publication of it.

Nothing in that list covers body composition, ageing, sleep or any long-term outcome in people. The ageing argument that ipamorelin is most often discussed under rests on general growth hormone biology rather than on ipamorelin data, which is the subject of ipamorelin and somatopause.

Is ipamorelin approved anywhere?

No. Neither development route, growth hormone release or postoperative gut recovery, reached registration. It has no authorisation from Health Canada, the FDA or the EMA. Health Canada's public advisory of 9 April 2026 on unauthorized peptides bought online names ipamorelin among its examples, and states that peptides in Canada are generally regulated as prescription drugs. The Canadian framework is set out in peptides and Canadian law.

In sport, growth hormone secretagogues are a named class on the World Anti-Doping Agency's prohibited list, and ipamorelin falls within it.

What is ipamorelin commonly confused with?

CJC-1295. The two are sold together, and the pairing is so common that the names blur. CJC-1295 is a GHRH analogue at a different receptor, and the name itself covers two different molecules; see what is CJC-1295 and CJC-1295 and ipamorelin. No published study has examined the combination.

Tesamorelin. Also a GHRH analogue, and unlike ipamorelin an approved drug for one indication. The contrast in evidence is set out in tesamorelin vs ipamorelin and what is tesamorelin.

Ghrelin and the GHRPs. Ipamorelin shares a receptor with ghrelin, GHRP-6, GHRP-2 and ibutamoren. Sharing a receptor does not mean sharing an effect profile, which is the whole point of the selectivity paper.

Plasma half-life and duration of effect. A two-hour half-life and a growth hormone peak at 40 minutes are different measurements from the same study. Neither describes what happens after repeated exposure, which has not been studied in people.

Supplied here for laboratory use: Ipamorelin. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.

The results above describe the compound in the animals and people studied. They are not evidence about any laboratory reagent. Nothing here is medical, dosing, or therapeutic guidance.

Frequently asked questions

Is ipamorelin a peptide hormone? It is a synthetic peptide, not a natural hormone. Its five residues include three that do not occur in proteins, and it was designed in a pharmaceutical chemistry programme. It mimics the action of ghrelin at the ghrelin receptor, which leads the pituitary to release its own growth hormone. It does not contain or supply growth hormone.

Who made ipamorelin? Novo Nordisk. Raun and colleagues in the company's growth hormone biology department described its development and pharmacology in 1998. Its later clinical development for postoperative ileus was sponsored by Helsinn Therapeutics, according to the ClinicalTrials.gov registrations for both phase 2 trials. Neither programme led to an approved product.

Does ipamorelin raise cortisol? In the 1998 swine study it did not raise ACTH or cortisol beyond the levels seen after GHRH, while GHRP-6 and GHRP-2 did. No published human study has measured cortisol after ipamorelin against a comparator, so the finding is established in pigs and untested in people.

Has ipamorelin been tested in a clinical trial? Yes, for recovery of gut function after bowel surgery, not for anything to do with growth hormone. The published phase 2 trial found no significant difference from placebo in time to tolerating a solid meal. A second, larger phase 2 trial is registered as completed in 2014 with no results posted.

Selected Research References

  1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. pubmed.ncbi.nlm.nih.gov/9849822
  2. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999;16(9):1412-1416. pubmed.ncbi.nlm.nih.gov/10496658
  3. Johansen PB, Nowak J, Skjaerbaek C, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106-113. pubmed.ncbi.nlm.nih.gov/10373343
  4. Svensson J, Lall S, Dickson SL, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. Journal of Endocrinology. 2000;165(3):569-577. pubmed.ncbi.nlm.nih.gov/10828840
  5. Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. Journal of Pharmacology and Experimental Therapeutics. 2009;329(3):1110-1116. pubmed.ncbi.nlm.nih.gov/19289567
  6. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2014;29(12):1527-1534. pubmed.ncbi.nlm.nih.gov/25331030

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.